Processing

Please wait...

Settings

Settings

Goto Application

1. EP3326645 - METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN SVCAM AND/OR SMADCAM LEVELS

Office European Patent Office
Application Number 17192860
Application Date 24.10.2011
Publication Number 3326645
Publication Date 30.05.2018
Publication Kind B1
IPC
A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
G01N 33/566
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
566using specific carrier or receptor proteins as ligand binding reagent
G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
CPC
G01N 33/566
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
566using specific carrier or receptor proteins as ligand binding reagents ; where possible specific carrier or receptor proteins are classified with their target compounds
G01N 33/6893
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
6893related to diseases not provided for elsewhere
G01N 2333/70503
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
705Assays involving receptors, cell surface antigens or cell surface determinants
70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
G01N 2333/70546
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
705Assays involving receptors, cell surface antigens or cell surface determinants
70546Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
G01N 2333/7056
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
705Assays involving receptors, cell surface antigens or cell surface determinants
7056Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
G01N 2500/00
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2500Screening for compounds of potential therapeutic value
Applicants BIOGEN MA INC
Inventors CHACKERIAN ALISSA A
Designated States
Priority Data 11838481 24.10.2011 EP
40635810 25.10.2010 US
40636510 25.10.2010 US
Title
(DE) VERFAHREN ZUR BESTIMMUNG VON UNTERSCHIEDEN IN EINER ALPHA-4-INTEGRIN-AKTIVITÄT DURCH KORRELATION VON UNTERSCHIEDEN IN SVCAM- UND/ODER SMADCAM-EBENEN
(EN) METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN SVCAM AND/OR SMADCAM LEVELS
(FR) PROCÉDÉS DE DÉTERMINATION DE DIFFÉRENCES DANS L'ACTIVITÉ ALPHA-4 INTÉGRINE PAR LA CORRÉLATION DE DIFFÉRENCES DES TAUX DE SVCAM ET/OU DE SMADCAM
Abstract
(EN)
Provided herein is a method of monitoring the change of the alpha-4 integrin activities in an individual by correlating with the soluble vascular cell adhesion molecule (sVCAM) and/or soluble mucosal addressin cell adhesion molecule (sMAdCAM) levels. Particularly, this method can be used, for example, to evaluate the pharmacokinetics and pharmacodynamics (PK/PD) of an alpha-4 integrin inhibitor used to treat a disease associated with pathological or chronic inflammation.

(FR)
La présente invention concerne un procédé de surveillance de la modification des activités alpha-4 intégrine chez un individu par la corrélation avec le taux de molécule d'adhésion cellulaire vasculaire soluble (sVCAM) et/ou de molécule d'adhésion cellulaire adressine mucosale soluble (sMAdCAM). En particulier, ce procédé peut être utilisé, par exemple, pour évaluer la pharmacocinétique et la pharmacodynamique (PK/PD) d'un inhibiteur d'alpha-4 intégrine utilisé pour traiter une maladie associée à une inflammation pathologique ou chronique.